Clinical trials: Skin Diseases, Papulosquamous
Oral Lichen Planus
Evaluation of Salivary Level of miR-155 and IL-10 in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid
Thirty patients will be recruited from the outpatient clinic of the faculty of dentistry.fifteen systemically healthy individuals with normal mucosa and fifteen atrophic/erosive oral lichen planus patients.
- Trial name
- NCT03871114
- Testing
- Triamcinolone Acetonide in orabase
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cairo University
Psoriasis
Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications
The purpose of this study is to determine the efficacy for Bicillin L-A, administered intramuscularly in a dose of 2.4 million units every three (3) weeks, for the treatment of chronic, plaque-type psoriasis unresponsive to…
- Trial name
- NCT00427609
- Testing
- Bicillin L-A
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Tennessee
Oral Lichen Planus
Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus
Lichen planus is an inflammatory disorder of unknown aetiology affecting the stratified squamous epithelia, with an estimated global prevalence of 0.22 to 0.5 %.
- Trial name
- NCT06260904
- Testing
- Prednisolone, Apremilast, Methotrexate
- Where
- India
- Volunteers
- 64 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Arthritis, Psoriatic
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- ICONIC-PsA 1 (NCT06878404)
- Testing
- Icotrokinra, Active reference comparator
- Where
- 155 sites in United States, Argentina and 14 more
- Volunteers
- 552 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
Randomized, double-blind, 24-week study of patients with psoriatic arthritis comparing alefacept + methotrexate (MTX) vs. placebo + MTX followed by a 24-week open-label extension with only alefacept + MTX treatment.
- Trial name
- NCT00659412
- Testing
- Alefacept, Methotrexate
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Astellas Pharma Inc
Psoriasis, Psoriasis Arthritis
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
The inclusion criteria for this study were patients aged 18 to 75 years with a confirmed diagnosis of psoriasis by a dermatologist or psoriatic arthritis by a rheumatologist.
- Conditions
- Psoriasis, Psoriasis Arthritis, Biologics
- Trial name
- SMILE (NCT07149792)
- Testing
- Prescreen platform, biologics treatment
- Where
- 2 sites in Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Enthesopathy
Comparation of Ultrasonic Imaging of Enthesopathy in Patients With Psoriatic Arthritis and Psoriasis
Psoriatic arthritis(PsA) and psoriasis(Ps) are two systemic inflammatory diseases linked with rash of psoriasis, but there's still great controversy regarding the exact relationship between them.
- Trial name
- NCT02962271
- Testing
- Musculoskeletal Ultrasound
- Where
- China
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Psoriasis
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.
- Trial name
- STYLE (NCT03123471)
- Testing
- Apremilast
- Where
- 45 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Amgen
Psoriasis, Microbial Colonization
Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis
The human microbiota corresponds to an extremely rich and varied set of microorganisms that colonize our various epitheliums from birth, including the intestine, lungs and skin, where they interact continuously with our immune…
- Trial name
- REMISSIOn (NCT06055699)
- Testing
- Fecal sampling, Blood sampling
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis, Palindromic Arthritis
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
Social determinants of health (SDoH), defined by the World Health Organization as "the conditions in which people are born, grow, work, live and age and the wider set of forces and systems shaping the conditions of daily life"…
- Conditions
- Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- RAISE (NCT05715463)
- Testing
- Resource sheets, Community Resource Specialist, Nurse Navigator
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Brigham and Women's Hospital
Psoriasis
Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation
The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation.
- Trial name
- IMMPRESS (NCT03518047)
- Testing
- risankizumab
- Where
- 6 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AbbVie
Psoriasis, Skin Diseases
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT06066125
- Testing
- AK111
- Where
- 34 sites in China
- Volunteers
- 351 people
- Sponsor
- Akeso
Psoriasis
A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
This is a Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in…
- Trial name
- NCT00109317
- Testing
- Raptiva (efalizumab)
- Volunteers
- 686 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis, Psoriatic Arthritis
A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector
The main purpose of this study is to evaluate how well the autoinjector works in a group of people who are likely to use the autoinjector for injecting their medicine in the future.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
- Trial name
- NCT00643526
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Centocor, Inc.
Psoriasis
Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events.
- Trial name
- NCT01320293
- Testing
- Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of North Carolina, Chapel Hill
Psoriatic Arthritis, Rheumatoid Arthritis
Optimization of Psoriatic and Seronegative Rheumatoid Arthritis Patients Selection and Treatment Outcomes of Biologic Therapies.
Different classes of biological targeted therapies (b-DMARDs) are available for psoriatic arthritis (PsA) and seronegative rheumatoid arthritis (RA) (TNF inhibitors, anti-IL23, anti-IL17).
- Trial name
- NCT05767814
- Testing
- Phenotyping of synovial immune and stromal cells
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 135 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Psoriatic Arthritis
Initial Treatment With Golimumab in Early PsA
The investigators will perform a 22-week randomized, double-blind, placebo-controlled trial of golimumab + methotrexate (MTX) versus methotrexate alone in methotrexate-naïve patients with Psoriatic Arthritis (PsA).
- Trial name
- NCT01871649
- Testing
- golimumab, methotrexate
- Where
- 2 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Psoriatic Arthritis
Stronger Together Psoriatic Arthritis Wellness Study
Patients diagnosed with psoriatic arthritis (PsA) confront decisions about how to treat their disease, interact with their health care providers, and modify lifestyle choices that may improve treatment outcomes.
- Trial name
- NCT05652608
- Testing
- Immune Strength
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Global Healthy Living Foundation
Psoriatic Arthritis
HUmira in Psoriatic Arthritis
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis, which has a estimated prevalence of 0.3 - 1 %.
- Trial name
- HUPSA (NCT01465438)
- Testing
- Adalimumab
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Plaque Psoriasis
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the…
- Trial name
- NCT06030076
- Testing
- Tildrakizumab
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Almirall, S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.